Oncology Flashcards

1
Q

craniopharyngioma

A

Suprasellar tumour
relatively benign
arises from floor of 3rd ventricle to the pituitary gland (infundibulum)
Usually age 10-15 years
Pressure effects- headaches, diplopia, visual disturbance, short stature, amenorrhoea

MRI look- may be single or multiple cysts filled with thick oily fluid high in protein, blood products, and/or cholesterol. >90% have calcification rimming
Rx- surgical resection and Rtx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Raised AFP

A

-Hepatocellular carcinoma

-Non seminomatous germ cell tumours - Embryonal tumours (poorly differentiated), dermoid
yolk sac tumour (endodermal sinus tumour, infantile embryonal tumour)

-Hepatoblastoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Testable genetics

A

Ewings
- t(11:22)

Alveolar Rhabdomyosarcoma

  • t(1;13)
  • This is pathognomonic for this kind of rhabdo
  • Alveolar is worse prognosis with 100% mortality (cf embryonal rhabdo)

Neuroblastoma
-MYCN amplification = poor prognosis

ATRT

  • Loss INI1/SMARCB1.
  • Poor prognosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Li fraumeni syndrome

A
  • Rare
  • AD
  • pre-disposes carriers to cancer development
  • AKA sarcoma, breast, leukaemia and adrenal gland (SBLA) syndrome
  • Germline loss of TP53
  • Screening exam, bloods, whole body MRI, USS etc decreases mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

VOD

A

If post HSCT occurs within 30 days. Occurs in 15% of ppl

  • Hepatomegaly
  • RUQ pain
  • Jaundice
  • Ascites
  • Fluid overload

Risk factors:

  • 1 young age
  • prior liver disease
  • abdominal radiation
  • repeated transplants
  • neuroblastoma
  • familial Haemophagocytic lymphohistiocytosis

If severe form mortality

Rx:
Heparin, ursodeoxycolic acid
Consider defibrotide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Important translocations

A

Alveolar rhabdo (pathognomonic)

  • t(1:13) or t (2;13)
  • Terrible prognosis

t(8;14)
- may be burkitts lymphoma (Mature cells)
OR B-ALL (immature cell)

22q12 ESWR1

  • sarcomas
  • if t(11;22) in bone then it is Ewings

Infantile fibrosarcoma (age <1 year)

  • t(12;15) is pathognomonic
  • Infantile fibrosarcoma responds excellently to Tyrosine kinase inhibitors and spares children from mutilating surgeries
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Small round blue tumours

A

H&E stain –> blue = nucleus
Large nucleus, small cytoplasm
Big nucleus = rapidly dividing

  • EWINGS
  • NEUROBLASTOMA
  • WILMS
  • RHABDOMYOSARCOMA
  • LYMPHOMA
  • Medulloblastoma
  • Retinoblastoma
  • Anaplastic hepatoblastic (NOT fetal or embryonal hepatoblastoma)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Wilms (nephroblastoma)

A

Embryonal tumour
Small round blue cells
Most common malignant renal tumour of childhood
6% of paediatric tumours
From infancy to 5 years. Very unlikely past then.
-Rarely dx <6months
-Best characterised gene is Wt1 deletion on 11p13
METS to LUNGS
95% unilateral
5% bilateral (at same time OR contralateral later in life)
90+ survival (unless anaplastic)

Can be syndromic or non syndromic
If known risk q3MONTHLY USS until age 8

If bilateral at same time -more aggressive chemo. Try to spare nephrons with surgery. If not remove –> dialysis 1-2 years –> transplant

20 years ESRF risk:
1% unilateral
12% bilateral

Sx: 
Unilateral large mass
Abdo pain
Fever
Painless gross haematuria
HTN in 25% (increased renin from tumour)
Complications:
Bleed into tumour (with rapid enlargement)
Anaemia 
Thrombus --> 5-10% can extend into IVC
Acquired vWF deficiency

IX:
XR, USS, CT, MRI
USS is good to look at cystic vs solid, and differentiate from adrenal tumours

DDX:
Mesoblastic nephroma (<3 months, solid tumour, mostly benign)
Clear cell tumour (look for bone mets)
Rhabdoid tumour kidney (look for brain mets; poor prognosis, rare; often haematuria presenting complaint)

Prognostic factors:
Age (<2 =better), stage, tumour weight, loss of heterozygosity at 1p and 16q (poorer prognosis), anaplasia

Rx:
Low risk- actinomycin- D and vincristine
High risk: Actinomycin D, Vinc, Doxorubicin

Late effects:
2nd malignancy
cardiac toxicity
pulmonary disease
renal failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Syndromes associated with Wilm’s

A

WAGR syndrome

  • WT1 DELETIONS (11p13)
  • Wilms
  • Anirida (100%) = no iris. PAX6 del
  • GU
  • Retardation

Denys-Drash Syndrome

  • WT1 MISSENSE
  • Nephropathy (early onset renal failure)
  • male hermaphrodism

Beckwith Wiedeman

  • 11p15
  • Wilms and hepatoblastoma
  • Organomegaly, macroglossia, hemihypertrophy

FWT1 and FWT2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Doxorubicin

A

ADD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sarcoma- soft tissue

A

Soft tissue malignancy

  • Rhabdomyosarcoma most common
  • Others include liposarcoma, fibrosarcoma, leiomyosarcoma etc
  • Rhabdomyosarcomas are chemo SENSITIVE
  • The rest are chemo RESISTANT and are treated with resection and radiation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Rhabdomyosarcoma

A

Most common soft tissue malignancy in children

  • Embryonal (unless alveolar) skeletal muscle
  • Small round blue cells
  • embryonal (60%) - NO translocations
  • Alveolar 25-40% (translocations 1;13 or 2;13) and are most often in trunk and extremities and have poor prognosis
  • chemosensitive
  • 3.5% of childhood cancers
  • Can occur anywhere but usually head and neck (including face, nasopharynx, midle ear, sinuses etc)
  • more likely alveolar in older children
  • Can disseminate early + LUNG METS
  • Alveolar METS everywhere incl BONE MARROW
  • Associated with neurofibromatosis and Li-Fraumeni syndrome

Sx:

  • Mass (may be painful)
  • Secondary sx from pressing on structures (anywhere from nose bleeds to cranial nerve palsies). Can often present with similar to common childhood conditions
  • If in extremities usually noticed after trauma and mistaken for haematoma
  • Can get vaginal rhabdo (grape like mass bulging through vaginal orifice)

Ix:
CT and MRI
Staging - bone scan, chest CT, BMA, biopsy

RX:

  1. pre-operative chemo
  2. resection
  3. post -op chemo (vinc, cyclophosphamide)
  4. +/- irradiation depending on stage and site

Survival:
Embryonal - 40-90%, still curable if mets
Alveolar 0-60% incurable if mets

Risk factors:
Older = bad
Histology and staging (mets and site)

Late effects:

  • Impaired bone growth from radiation
  • second malignancy
  • Infertility from CYCLOPHOSPHAMIDE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Osteosarcoma

A

Malignant bony tumour

  • Most likely to occur in second decade
  • Highest risk during adolescent growth spurt
  • INCREASED risk if has had hereditary retinoblastoma or Li-Fraumeni syndrome (TP53), previous Rtx
  • Can be primary or secondary (previous RTX to bony areas!)
  • Chemosensitive

-Site = METAPHYSES of long bones

SX:

  • local pain and swelling + limp
  • often hx of trauma
  • Bloods are often normal, may have raised ALP or LDH
  • XR changes –> sunburst pattern (new bony formation), SCLEROTIC destruction (blastic), may have some lytic
  • Histology + spindle cell-producing osteoid
  • Genetics - TP53 found in 3-10% (Li-fraumeni)

Mets: Lung + bones

DDX:
Ewing’s, osteomyelitis

Rx:

  • Chemo (doxorubicin, cisplatin, HDmtx, ifosphamide
  • Surgery of primary tumour
  • Resect lung mets
  • laregly RESISTANT to Rtx

Prognosis:
W/o mets at least 70%
with mets <20%

Late effects:
SNHL
Cardiac toxicity (anthracyclines)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Ewings Sarcoma

A

Malignant bony tumour

  • Most likely to occur in second decade
  • Chemo sensitive
  • Ewing >osteosarcoma if <10 year of age

Site: DIAPHYSES of long bones, flat bones
METS TO LUNGS and BONE MARROW

Sx: Local pain, fever, swelling, weight loss

XR- primarily LYTIC tumour, multi-laminar periosteal reaction/elevation (onion-skinning)
Histo –> small round blue cells
t(11;22) found in 90% DIAGNOSTIC

IX:

  • MRI + 2x CT guided biopsy from andt least 2 sites
  • staging with CT chest

DDX:

  • osteomyelitis
  • eosinophilia granuloma
  • neuroblastoma
  • rhabdomyosarcoma
  • lymphoma

Rx:
Chemo
RTX SENSITIVE +/-surgery

Prognosis:
w/o mets 60% cured
with mets 20-30% cured

Late effects:

  • cardiotoxicity
  • secondary osteosarcoma from Rtx
  • Late relapses (as long as 10 years!)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Translocations in cancer

A

Results in two DNA binding domains (target genes) fused together and two regulatory domains (on and off switches) together instead of one binding and one regulatory together.

Because missing regulatory domain switch stays ON
= Mutant transcription factor –> cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Retinoblastoma

A

Embryonal tumour

  • most common intra-ocular cancer in childhood
  • 4% malignancies
  • Most cases <5 years old, median age 2
  • At least 2/3 unilateral
  • Hereditary and sporadic
  • Hereditary associated with younger age and bilateral retinoblastoma
  • Loss of function of RB1 gene on chromosome 13
  • Small round blue cell tumour with rosette formation
  • Generally presents with leukocoria or strabismus
  • Advancing disease results in orbital inflammation, redness and pupillary distortion
  • pain if glaucoma present

Can MET to CSF and spinal cord
AT RISK of trilateral tumour (pineal ) tumour which can occur at the same time or any time after (presetns with HEADACHES AND VI NERVE PALSY

DDX:
Other causes of leukocoria –> ROP, coats disease, cataract, persistent hyperplastic primary vitreous

IX:
Dx made based on ophthalmological findings (under GA) as imaging is not diagnostic and biopsy is contraindicated
Orbital USS, CT and MRI useful for staging

Rx:
Focal chemo (etoposide, vincristine, carboplatin)
If too large then enucleation of the eye
If bilateral - focal chemo to reduce size + focal laser photocoagulation or cryotherapy
+/-irradiation (significant deformity + increased risk of 2ndary tumour)

Prognosis - good >95%
Continue routine examination of eyes until age 7
If spread outside orbit, prognosis is poor
Those with RB1 mutation increased risk of secondary tumours, esp if exposed to radiation

Late effects:
Usually related to Rtx
- cataracts
-poor orbital growth deformities
- lacrimal dysfunction
- late retinal vascular injury
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Neuroblastoma

A

Most comon extra cranial solid tumour

  • 8-10% childhood malignancies
  • median age dx 22 months with 90% dx by 5 year old
  • Can occur at any site of sympathetic nervous tissue. about 50% adrenals, the rest along sympathetic ganglion
  • mets more likely if >1 year old
  • mets lymph nodes, long bones, skull, bone marrow, liver and skin
  • lung and brain mets are RARE
  • Associated with neural crest disorders such as hirschsprungs, NF1 and central hypoventilation syndrome
  • Associated with Beckwith wiedemann syndrome or isolated hemihypertrophy

3 types of risk

  1. High risk and malignant and aggressive (local/mets)
    - MYCM AMPLIFICATION
    - 70% survival
    - HIGH dose chemo 13-18 months –> causes aplastic anaemia so need autologous stem cell rescue + surgery + radiation +/- MIBG radioactive isotope, chimeric (immune therapy), retinoic acid
  2. Intermediate risk local or metastatic <18 month
    - 95% survuval
    - 2-8 cycles mod chemo +surgery
    - No transplant, no chimeric, rarely radiation
  3. Low risk, localised and STAY that way
    - 97-99% survival
    - small ones in babies usualy resolve spontaneously
    - larger ones cured with resection

Sx:
Can present with syndrome (see slide)
Great mimicker so can be non-specific and hard to dx
-metastatic disease can present with systemic sx, bony pain, cytopenia, proptosis, periorbital ecchymoses,.
-localised disease can present as asymptomatic or mass-related sx such as spinal cord compression, bowel obstruction and SVC syndrome

Dx:

  • Imaging - plain film, CT, MRI
  • Tumour markers such as catecholamine metabolites (HVA and VMA) in urine is elevated in 95% cases and helps to confirm dx
  • biopsy gold standard but dx can be made if small round blue cells in bone marrow and urine catecholamines are high
  • Staging - CT chest and abdomen, bone scan and at least 2x BMA

Neurobolastoma risk:

  • met vs local
  • easy to resect vs not
  • age (older = worse. cut off age 18 months)
  • histology
  • genetics = MYCN amplification and 11q missing are bad
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Syndromes associated with neuroblastoma

A

HORNER SYNDROME

  • neuroblastoma originating in superior cervical ganglion
  • Unilateral ptosis, myosis, ahydrosis
  • Sx DO NOT resolve with tumour resection

OPSOCLONUS-MYOCLONUS-ATAXIA syndrome

  • paraneoplastic syndrome of autoimmune origin
  • myoclonic jerking and random eye movement +/-ataxia
  • usually associated with lower risk tumour
  • may not resolve with tumour removal
  • can be progressive

SWEATING and HTN
- catecholamine release from tumour

NEUROCRISTOPATHY SYNDROME

  • when neuroblastoma associated with other neural crest syndrome such as hirschsprungs, and congenital hypoventilation syndrome
  • Germline mutation of PHOX2B

KERNER-MORRISON SYNDROME

  • tumour secreation of vasointestinal peptides causing intractable secretory diarrhoea
  • tumours generally biologically favourable

PEPPER SYNDROME
- massive involvement of the liver with mets disease +/- respiratory involvement

HUTCHINSON SYNDROME
- irritability and limp in young child associated with bony and bone marrow mets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Chimeric (Ch14.18) monoclonal antibody

A
  • targets “GD2” which is present on healthy and unhealthy nerve cells
  • antibody dependent cellular cytotoxicity (ADCC)
  • attacks healthy nerves = ++pain. need morphine and ketamine
  • causes physiological instability, fever, oedema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Hepatoblastoma

A

Most common liver malignancy of childhood
<1% malignancies of childhood (liver tumours account for 1%, hepatoblastomas about 65% of this)

  • usually in children <3 years
  • Alterations in APc/beta-catenin pathway

-Environment predisposition LBW <1000g (38 x relative risk) –> not high enough to screen for

  • 15% have genetic predisposition
  • -> BWS
  • -> FAP
  • -> Li-fraumeni, T18, NF-1, ataxia telangectasia, fanconi anaemia, TS

Ix:
AFP raised (non-specific as high in HCC and GCTs) –> but used for monitoring response
Can also have raised BHCG
Biopsy gold standard

RX:
1. resection key to cure (as much as 85% is fine with regeneration in 3-4 months!)
2. chemo in most Cisplatin/carboplatin (also treats mets) + sodium thiosulpahte (protects against SNHL)
vinc and doxorubicin
3. Transplant if unable to resect
+/- post-transplant chemotherapy

The ONLY CONTRAINDICATION to TRANSPLANT:
persistence of viable extrahepatic disease after chemo

Prognosis:

  • > 90% with low staged with surgery and post chemo
  • 60% if unresectable tumour
  • 25% if pulmonary mets
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Sodium thiosulphate

A
  • antidote for cyanide poisoning

- infuse soon after giving cisplatin prptects against SHNL w/o compromising efficacy of Rx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Germ cell tumours

A
  • tumour that begins in cells that give rise to eggs or sperm
  • can occur almost anywhere in the body and can be malignant or benign
  • 1/3 arise in gonads
  • 2/3 are extragonadal as arise from aberrant migration and occur in the MIDLINE
  • appearance may mimic any cell in embryo (yolk) or extra embryonic (chorion)
-types include
teratoma (mature and immature) --> benign
Germinoma
embryona carcinoma
endodermal sinus tumour (raised AFP)
choriocarcinoma (raised BHCG)

Primary sites:

  • Gonadal - testes 25% (adolescents), ovaries 10% (adolescents
  • CNS–> pineal, suprasellar, rare and aggressive
  • cervical –> rare, teratomas/infants
  • MEDIASTINAL –> 5% (adolescents) associated with KLINFELTERS
  • Retroperitoneal 10% infants/children
  • SACROCCOYGEAL 50% infants/children

Sx: present as mass lesions
If in CNS presents often as diabetes insipidus in adolescents. Or as precocious puberty or panhypopit

RX:
1. Surgery
2. Cisplatin/carboplatin if cannot be resected
+/-radiation (intracranial chemo +radiation as cannot resect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Teratoma

A

GCT

  • derived from more than one germ layer
  • cell of origin is totipotent so can resemble anything
  • tumour components resemble normal tissues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Nephrogenic rests

A

Nephrogenic rests (NR) are abnormally persistent clusters of embryonal cells, representing microscopic malformations (dysplasias) of the developing kidney.

Though NR are best known as precursors of Wilms tumor (WT), many alternative fates are observed, and most rests are destined for eventual atresia

25
Q

Proto-oncogene

A

A normal gene which, when altered by mutation, becomes an oncogene that can contribute to cancer. Proto-oncogenes may have many different functions in the cell. Some proto-oncogenes provide signals that lead to cell division and growth.
Other proto-oncogenes regulate programmed cell death (apoptosis).

If it becomes an oncogene –> unregulated cell growth and division –> malignancy

26
Q

PTEN syndrome (AKA Cowden syndrome)

A
  • Autosomal dominant
  • Mutations of tumour suppressor gene PTEN
  • Usually manifests in 2nd to 3rd decade with multipe harmatomas (smooth pink or white papules) on palate, gingival, buccal and labial mucosa.
  • harmatomas on face
  • Dysmorphism
  • -> macrocephaly
  • -> harmatomas
  • -> lipomas
  • -> AVM’s
  • -> learning difficulties/ASD

Increased risk of thyroid, breast and colon cancer

Screening

  • for thyroid and 10-12 years
  • breast and colon at 25-30 years old
27
Q

Solid tumours (extracranial)

A

Most common childhood cancer (1/3)
number 2 are intracranial tumours

  • nephroblastoma, hepatoblastoma, retinoblastoma
  • sarcomas
  • osteosarcomas and ewings
  • germ cell tumours
  • thyroid
  • melanoma
  • other
28
Q

CNS tumours

A

2nd most common malignancy of childhood

  • 22% 0-14 years
  • 10% 15-19 years
  • leading cause of mortality
  • 70-75% 5 year survival

Infratentorial >supratentorial because there is a long developmental stage of the cerebellum in children

Most common:

  • medulloblastoma (1)
  • PNETS (Primitive neuroectodermal tumor )
  • ATRT
  • Ependymoma
  • gliomas
  • pilocystic astrocytoma (NF-1)
  • craniopharyngiomas

Rare: Germ cell tumour

Sx:

  • recurrent a.m headaches, N+V, lethargy = raised ICP
  • irritability
  • listlessness
  • visual disturbances
  • starbismus
  • FTT
  • progressive macrocephaly
  • papilloedema
  • older children –> localising neurological signs
  • change in personality
  • ‘larning disabilities’ in older children
  • late sign is sudden onset of CN palsies esp III, VI, VII

IX:

  • MRI brain and spine
  • Biopsy (thalamic and central tumour) +/- resection if safe (posterior fossa, cortex)
  • LP for CSF cytology
  • AFP and B-HCG (GCT) blood and CSF
  • pituitary hormones

Rx:
Multimodal approach esp as developing brain
Late effects are a significant limiting factor
therefore goal is minimal therapy to achieve a cure

29
Q

Diencephalon

A

the caudal (posterior) part of the forebrain, containing the epithalamus, thalamus, hypothalamus, and ventral thalamus and the third ventricle.

Suspect if visual disturbance

30
Q

Medulloblastoma

A

most common CNS tumour approx 20%

  • primitive neuroectodermal tumour
  • peask age 3-9 years, M>F
  • post fossa (cerebellum, usually vermis)
  • up to 1/3 metastatic disease at presentation (CSF, nodule seeding in brain or spine)

On MRI:

  • T1 scan enhancement
  • Cystic spaces seen on T2

Prognosis based on:

  • ability to resect (do better if <1.5cm2 residual tumour)
  • stage ( AR if localised only aka M0, HR if M1-M4)
  • histology ( if extensive nodularity and young child can rx with chemo only and no have to use Rtx)
  • molecular markers
  • Age > 3 years (<3 years do worse can cannot irradiate brain and space)

Ix:
-repeat MRI of spine and CSF at least 10/7 after resection

Rx:

  1. maximal tumour resection
  2. Rtx –> reduced dose and tumour bed boost if AR; high dose RTX if HR
  3. adjuvant during and after Rtx –> St Jude’s
    - Cisplatin, vincristine, cyclophosphamide
    - HD chemo is HR with autologous stem cell rescue (don’t need for AR)
Prognosis 5 years:
AR --> 75-80%
HR --> M1 about 60%  
      --> M2/M3 about 40%
      --> SJMB-96 M1-M3 66%
31
Q

Genetic conditions and predisposing to Medulloblastoma

A

GORLIN SYNDROME

  • AKA basal-cell nevus syndrome
  • 3% will get MB
  • PTCH pathway mutation

TURCOT’s SYNDROME

  • mismatch repair cancer syndrome (Lycnh, HNPCC)
  • Increased risk of CNS tumours and cororectal polyposis/cancer
  • high grade gliomas and MB in childhood/adolescence

LI-FRAUMENI SYNDROME

  • TP53
  • bimodal peak <10 years abd 20-40 years
  • ASTROCYTOMAS&raquo_space; MB
32
Q

Medulloblastoma genetic subtypes

A

4 types
-different histology and age onset

  1. WNT activated
    - monosomy 6, classic histology
    - do well
    - 90% long term survival
  2. SHH activated
    - PTCH pathway
    - lateral tumours
    - nodular desmoplastic
    - INFANTS have excellent prognosis
    - TP53 mutated tumour very poor prognosis
  3. Non-WNT/non SHH
    - Group 3
    - -> MYC amplification, large cell ANAPLASTIC, poor outcome
    - Group 4
    - -> MYCN amplification, cassic or large cell anaplastic, intermediate outcome

These guys are stratified into SJMB12 treatment and guides chemo + RTX

33
Q

PNETs

A
  • Primitive neuroectodermal tumours
  • are embryonal tumours
  • undifferetnitated or poorly differentiated
  • median age 5.5 years
  • M:F 1:2
  • cerebral hemispheres&raquo_space; suprasellar or spinal
  • Grade IV tumours
  • poor prognosis cf MB
  • <3 years is very poor prognosis
34
Q

ATRT

A

Atypical Teratoid/Rhabdoid tumour

  • Deletion or mutation in INI1 gene (aka SMARCB1 gene) in tumour
  • Highly malignant
  • Usually occurs <2 years of age
  • about 15% children <3 years old with CNS
  • short hx, aggressive
  • occurs anywhere in brain and spine

MRI:
- Cystic and calcifications (subtle)

Genetics:
- can be germline mutation –> if so at risk fro renal and soft tissue tumours

  • GTR of tumour assoc with longer median survival (12.5 months vs 9.25 months)
  • chemo curative in small minority
  • early Rtx used in majority of survivors if >3 years old
  • unclear if Craniospinal irradiation necessary
35
Q

Ependymoma

A
  • originates from cells lining ventricle or central canal of the spinal cord
  • neoplastic ependymal cells
  • third most common CNS tumour (10%)
  • 90% intracranial with 70% in the post fossa

Poor prognosis if:
- <3 years old
- Anaplastic
-

36
Q

Pilocytic astrocytoma

A

AKA low grade gliomas

  • low grade tumours
  • comprise the largest group of CNS tumours in children
  • most common is juvenile pilocytic astrocytoma –> 2/3 occur in POST FOSSA involving the cerebellum

-Associated with NF1 (optic pathway gliomas) –> also respond better to chemo

  • Large and cystic
  • Cause pressure effects and visual impairment (if involving the optic pathway
  • indolent –> can be stable or regress
  • 3 places –> posterior fossa (cerebellum), supratentorial (optic pathway),
  • Almost all tumours involving the OPTIC pathway are JUVENILE PILOCYTIC ASTROCYTOMA

Histo:
low to mod cellularity with ROSENTHAL FIBRES

Genetics: single pathway
- (B) RAF pathway aberration –> MEK inhibitors disrupted

Rx:

  • usually just observe with interval examinations and periodic CNS imaging
  • surgery +/- chemo (if non-resectable) +/_ RTX if symptomatic exp if visual disturbances
  • chemo –> carboplatin, vinc, vinblastine

Prognosis
85-90%

37
Q

High grade glioma

A

Locally infiltrative astrocytomas

2 kinds:

  1. Anaplastic astrocytoma (grade III)
  2. Glioblastoma multiforme (grade IV)

BUT <10% leptomeningeal spread at time of dx

Genetics poorly understood:
P53, high Ki67 (mitotic index)

Rx:

  1. surgery –> unlikely to get GTR
  2. Rtx + alkylating agents (TEMOZOLAMIDE)

Prognosis:
< 2 years progression free <20%

Prognostic factors:

  • degree of resection
  • grade
  • P53 expression (+ve =good prognostic factor)
  • proliferation index (high Ki67 = bad)
  • younger <3 years better prognosis
38
Q

Brainstem gliomas

A

10-20% of all brain tumours in children

  • 80% are DIFFUSE gliomas
  • Diffuse intrinsic pontine glioma carries the WORST prognosis

Dx:
MRI changes –> diffuse enlargement of brainstem, particularly pons
- T1 hypointense
-T2 hyperintense

Often will have ataxia and nerve palsies (particularly VI)

Rx:
Rtx (palliative)standard of care
Chemo of no benefit
Biologicals are being tested

Prognosis:
<10%

39
Q

Diffuse brainstem pontine glioma

A

A common type of brainstem glioma
- usually dx 5-10 years old
- Grade II-IV BUT prognosis based on mutation landmark = Histone H3.3 NOT grade
H3.3 gene mutations do worse
- 80% have H3.3 gene mutation (histone = protein replication and formation)

Sx:
Classic triad
- Cerebellar signs (ataxia, dysmetria, dysarthria)
- Long tract signs (increased tone, hyper reflexia, clonus, +ve babinski, motor deficit)
- isolated or multiple nerve palsies (uni or bilateral)

Ix:
MRI diagnosis (+clinical signs)
- T2 hyperintense
-T1 hypotense (usually)
-  >50% in PONS
- Diffuse changes
-BASILAR artery encasement in >50%

-Biopsy NO effect of survival so only if clinical trial available and trained surgeons

Prognosis:
At 2 years, approx 20% with <10% chance of no disease progression

40
Q

Late effects of CNS tumour Rx

A

NEUROCOGNITIVE:
-serial decrease in IQ <7 years –> as in declines relative to peers as not progressing in learning
–> if at least 7 years old when IQ projection is -0.42 pts/year
–> If less than 7 years old IQ projection is -4.82 pts/year
(note in normal ppl IQ plateau’s about 16-20 years)

  • spatial learning difficulties
  • adaptive behaviour deficits
  • academic failure
  • Deficits worsen with time
Psychological
Endocrine/fertility- GH deficiency is most common followed by TSH and ACTH (and many others)
Neurological
Secondary cancers
Ototoxicity
Vision (life long damage)
41
Q

Dabrafenib

A

BRAF kinase inhibitor
- can be used in BRAF kinase +ve gliomas

Common side effects:
Hyperglycemia
Hyperkeratosis
Hypophosphatemia
Headache
These side effects are less common:
Fever.
Joint pain.
Hair loss.
Hand-foot syndrome (Palmar-planter erythrodyesthesia)
Increased Alkaline phosphatase.
Rash.
Back pain.
42
Q

Etoposide

A
  • Plant alkaloid/toperimase II inhibitor
  • Given IV
  • Used in Hodgkins lymphoma, non-hodgkins, acute non-lymphoblastic leukemia, testicular cancers

Common side effects:

  • bone marrow suppression
  • N+V
  • Hair loss
  • Hypersensitivity
  • constipation/diarrhoea
  • metallic taste in mouth
43
Q

CNS germ cell tumour

A

Present often as diabetes insipidus in teenagers
Can also present as precocious puberty or panhypopit

Two types:

  1. Germinoma
    - SUPRASELLA AND PINEALregion
    - CSF AFP/Beta HCG are negative or low
    - Good prognosis with RTX +/- EFS >80%
  2. Nongerminomatous germ cell tumour (NGGCT)
    - SUPRASELLAR region only
    - High AFP/BHCG
    - Neoadjuvant chemo and RTx EFS 40-75%
44
Q

Craniopharyngioma

A
  • Benign non-glial tumour (WHO grade I)
  • arises from Rathke’s pouch epithelium

-arise SUPRASELLAR and PARASELLAR region

Sx:
- Pituitary, hypothalamic, and optic nerve dysfunction

MRI:
Multicystic and solid enhancing mass
calcification common

Rx:
Resection and Rtx

45
Q

NF2

A

AD but 50% de novo
1 in 40,000

Less cafe au lait spots as NF1

  • increased risk of vestibular schwannomas and meningiomas
  • Increased risk of cataracts
  • tends to present later (early 20’s)
46
Q

incidence of cancer in children <15 years

A

149 per 10,000 per year

47
Q

incidence of leukemia in children <15 years

A

31% of all malignancies

  • ALL accounts for approx 80%
  • AML 10-15%
  • CML 2-3 %
  • Juvenile myelomonocytic leukemia (JMML) 1-2%
48
Q

leukaemia

A

-genetic abnormalites in a haemopoetic cell –> unregulated proliferation of clonal cells –> Bone marrow dysfunction/failure

Sx of bone marrow failure:

  • anaemia –> pallor, lethargy, poor appetite
  • thrombocytopenia –> bleeding, bruising, petechiae
  • Neutropenia –> infection, fever

Sx of organ infiltration:

  • Hepatomegaly, splenomegaly
  • lymphadenopathy
  • mediastinal mass (more common in MALE adolescents with T-ALL
  • Bone pain (night waking)
  • limp
  • testicular enlargement (esp relapse)

CNS infiltration:

  • headache
  • seizures
  • CN palsies
49
Q

ALL

A

80% B cell
20% T cell

Associated with chrom abn –> T21, bloom’s syndrome, Ataxia telangectasia, fanconi’s anaemia

Peak incidence 2-3 years
M>F
european and north american most likely

Standard risk:

  • 1-9 years old
  • WCC <50 (NOT for T cell)

High risk:

  • > 10 years
  • WCC >50 (NOT for T cell)
50
Q

Prognostic factors ALL

A

Favourable B-ALL

  • Trisomy 4,10 (part of hyperploid karyotype)
  • Hyperploidy (>50)
  • t(12;21) ->ETV6-RUNX1

Unfavourable B-ALL

  • t (4;11) ->MLL-AF4 rearranged
  • t(9;22) - BCR-ABL
  • hypoploidy (<44)
  • intrachromal amplification of chromosome 21 iAMP21

Favourable T-ALL
- t(10;14 -TLX/HOX11

Other poor prognostic factors include chemo sensitivity:

  • poor response to induction
  • If even MRD (>0.01%) is detectable at end of induction prognosis is worse unless intensify Rx
51
Q

ALL RX

A

INDUCTION: 4-5 weeks

  • Dex
  • Vinc
  • Asparaginase

If high risk add anthracyclines
- Doxo/danorubicin

-check MRD at this stage

CONSOLIDATION:

  • further reduce risk of burden of disease
  • intense CNS directed therapy (Dex, MTX, Cytarabine)
  • Minimal residual disease checked end week 14
  • If MRD 0.5% or more at end of week 14 then unlikely to be successful with chemo –> eligible for relapse/refractory ALL trial with new therapies +/- HSCT

MAINTENANCE

  • 2 years girls
  • 3 years boys
  • weekly low dose MTX and 6MCP
52
Q

Remission ALL

A

B cell ALL
>95%
- 92% for standard risk
- about 99% double/triple trisomies or ETV6-RUNX1
- 80% event free survival
- overall survival cure rates for all ages and all groups

T cell ALL
-higher risk group but overall survival about 90%

53
Q

Philadelphia +ve ALL

A

-Fusion of BCR and ABL1 creating a novel tyrosine kinase –> unregulated cell proliferation

  • Poorer prognosis
  • BUT now benefit from targeted treatment with tyrosine kinase inhibitors IMATINIB) by adding it to intense chemo
  • -> negates the need for transplant in many (unless relapse)
  • -> current 7 year relapse free survival >70%
54
Q

AML

A
  • Highest in infancy
  • EFS 50-60%
  • Overall survival 65-70%
  • Cumulative relapse 35-40% (major cause of death)

Present similar to ALL and also unique to AML is:

  • SC nodules BLUEBERRY MUFFIN rash (esp infants)
  • GINGIVAL HYPERPLASIA (infiltration)
  • DIC –> IF DIC and MYELOSUPPRESSIOn high SUSPECT AML
  • can get discrete masses such as chloromas (AML sarcomas)
  • -> can occur with out obvious BM involvement
55
Q

Chloromas

A
  • Granulocytic sarcomas from AML
  • Can occur in seeming isolation
  • Can be seen in bones, orbit and epidural space
  • typically associated with t (8;21) abnormality
    =M2 classification

Note: t (8;21) associated with good prognosis

56
Q

AML Rx

A

Anthracycline and CYTARABINE are the mainstays

INDUCTION:

  • anthracycline + cytarabine
  • assess disease status at end (remission = MRD Blasts <5%)

CONSOLIDATION:

  • optimise quality of remission to reduce rate of relapse
  • 2-3 course intense chemo
  • INCREASED dose of CYTARABINE
  • Consider HSCT
  • -> best way to prevent relapse but overall survival not increased due to high transplant related mortality

CNS directed therapy:

  • intrathecal to rx and prevent CNS disease
  • CYTARABINE
  • cranial irradiation considered if CNS refractory to chemo
57
Q

Acute lymphoblastic leukemia types

A
  1. Pre-B ALL
  2. T-cell
  • hard to tell Pre-B and T cell apart under microcscope
  • differentiate (immunophenotype) by flow cytometry
  • -> cluster differently (due to different epitopes expressed which act as receptors, ligands or in cell adhesion)
  • -> Different CD antigens. Flow cytometry with fluorescent antibodies i.e T cells CD2,3, 4,8. B cells CD 19,20
  1. Mature B cell/Burkitt leukaemia (lymphoma)
58
Q

Prognosis relapse ALL

A
  1. If >18 months off therapy and isolated extramedullary only then about 70% with only chemo

2.

59
Q

Syndromes with increased risk of Wilms

A

Hemihypertrophy +/- Beckwith syndrome is associated with Wilms tumour, hepatoblasoma, and adrenal carcinoma.

Several syndromes and congenital abnormalities are commonly associated with patients with Wilms.

WAGR syndrome – contiguous gene deletion syndrome that consists of Wilms tumour, aniridia, genitourinary abnormalities (cryptorchidism, streak ovaries, bicornate uterus, ambiguous genitalia) and mental retardation. Patients have a constitutional deletion of chromosome 11p13 where the Wilms tumor gene and the aniridia gene are located.

Denys-Drash syndrome – characterised by male pseudohermaphrodism, early-onset renal failure characterised by mesangial sclerosis, and the increased risk of Wilms tumour. Patients typically carry a missense mutation in the WT1 gene.

Beckwith-Wiedemann syndrome – characterised by hemihypertrophy, macroglossia and visceromegaly with a 3-5% risk of developing Wilms tumour. A variety of 11p15.5 abnormalities have been reported in patients with this syndrome.

Other syndromes or conditions with an increased risk of Wilms tumour include hemihypertrophy, sporadic aniridia, genitourinary abnormalities, Pearlman syndrome, Sotos syndrome, neurofibromatosis, von Willebrand disease. Genitourinary anomalies most commonly associated with Wilms tumour are hypoplasia, fusion and ectopia of the kidney, dupications of the collecting systems, hypospadias and cryptorchidism.